Karuna Therapeutics’ stock hits record territory after Bristol Myers’ $14 billion buyout deal
Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.